Craig Shapiro, MD
Nephrology · Jacksonville, FLNPI 1700824521
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,450 of the $57,363 with a category attached, or 86.2%. AstraZeneca accounts for 94.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $23,566 and has fallen 96.9% since, to $729 in 2025. Among nephrology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $198.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$54K
- Amgen$404
- Vifor Pharma, Inc.$385
- Otsuka America Pharmaceutical, Inc.$372
- Calliditas Therapeutics US Inc.$342
- OPKO Pharmaceuticals, LLC$135
- plus $1K from 23 others
Across 11 payments — averaging $50,280 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$484K
- GSK$69K
What the payments were for
- Speaking & faculty fees$49,45086%
- Travel & lodging$1,4743%
- Food & beverage$6,04211%
- Education$3971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 134 | $54,446 |
| Amgen(2 entities) | 33 | $404 |
| Vifor Pharma, Inc. | 19 | $385 |
| Otsuka America Pharmaceutical, Inc. | 19 | $372 |
| Calliditas Therapeutics US Inc. | 17 | $342 |
| OPKO Pharmaceuticals, LLC | 8 | $135 |
| Mallinckrodt Hospital Products Inc. | 7 | $125 |
| Novartis | 5 | $117 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $107 |
| Intuitive Surgical | 1 | $94 |
| Ardelyx, Inc. | 3 | $88 |
| Fresenius USA Marketing, Inc. | 5 | $83 |
| Bayer | 4 | $79 |
| Travere Therapeutics, Inc. | 8 | $72 |
| Scpharmaceuticals Inc. | 3 | $68 |
| Aurinia Pharma U.S., Inc. | 3 | $63 |
| Novo Nordisk | 2 | $53 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Boehringer Ingelheim | 2 | $51 |
| Mallinckrodt Enterprises LLC | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Boston Scientific | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Cormedix Inc. | 1 | $18 |
| GSK | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Akebia Therapeutics Inc | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,363 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 203 | $195,450 |
| JardianceEmpagliflozin | 53 | $44,793 |
| EntrestoSacubitril/Valsartan | 35 | $43,719 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $41,592 |
| RayaldeeCalcifediol | 22 | $35,888 |
| Sevelamer Carbonate | 15 | $12,141 |
| Valsartan | 178 | $5,865 |
| Nifedipine ErNifedipine | 145 | $5,162 |
| DapagliflozinDapagliflozin Propanediol | 11 | $4,431 |
| Clonidine | 35 | $3,643 |
| Doxazosin Mesylate | 176 | $3,535 |
| Tamsulosin Hcl | 130 | $3,218 |
| Eplerenone | 23 | $3,165 |
| Losartan Potassium | 275 | $2,771 |
| Calcitriol | 139 | $2,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $54,446 | $237,043237 claims |
| Boehringer IngelheimJardiance | $51 | $44,79353 claims |
| NovartisEntresto | $117 | $43,71935 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $135 | $35,88822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 756 nephrology providers in Florida.
Other nephrology in Jacksonville
- Fouad ChebibJacksonville$122K
- Jeremy CarlsonJacksonville$105K
- Hani WadeiJacksonville$53K
- Deborah PriceJacksonville$15K
- Tambi JarmiJacksonville$12K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.